Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00392925 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 177
- Enrollment target
NCT00392925: Completed Phase 2 study, sponsored by AstraZeneca.
NCT00392925 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 177 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (33% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00392925, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 177 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability, and effect on body weight of leptin, injected subcutaneously, in combination with pramlintide, injected subcutaneously.
Primary Outcome
Absolute change in body weight as measured in kilograms (kg) from baseline to Week 16. Baseline defined as Day 1 of randomized treatment.
Interventions
- DRUG metreleptin
- DRUG pramlintide acetate 360 mcg
- DRUG placebo-pramlintide 600 uL
- DRUG placebo-metreleptin 1 mL
- DRUG Pramlintide acetate 180 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
What the finished NCT00392925 record still lists
NCT00392925 is an interventional study that assigns participants to a tested intervention. The registered 177 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (33% higher).
The record links to 0 conditions, and to 5 interventions - of which metreleptin is the first listed.
NCT00392925 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00392925 about?
NCT00392925 is a clinical study titled "A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects". This study will evaluate the safety, tolerability, and effect on body weight of leptin, injected subcutaneously, in combination with pramlintide, injected subcutaneously.
What is the current status of trial NCT00392925?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 177 participants. The study started on 2006-10. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00392925?
The interventions under investigation include: metreleptin (DRUG), pramlintide acetate 360 mcg (DRUG), placebo-pramlintide 600 uL (DRUG), placebo-metreleptin 1 mL (DRUG), Pramlintide acetate 180 mcg (DRUG).
Who is sponsoring clinical trial NCT00392925?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00392925's enrollment target sits among peer trials
177 394th of 2000 higher than 1,607 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491551 · 177 participants · NA
Alcohol-ROC-Training
- NCT06108050 · 177 participants · Phase 1
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
- NCT06575712 · 177 participants · NA
Coping Skills Training for Symptom Management and Daily Steps (Step Up)
- NCT06674980 · 177 participants · NA
Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia